| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
|
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
Namenda is owned by Abbvie.
Namenda contains Memantine Hydrochloride.
Namenda has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Namenda are:
- US5061703
- US5061703*PED
Namenda was authorised for market use on 16 October, 2003.
Namenda is available in tablet;oral dosage forms.
Namenda can be used as treatment of moderate to severe dementia of the alzheimer's type.
The generics of Namenda are possible to be released after 11 October, 2015.
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 October, 2003
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: TABLET;ORAL
NAMENDA family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5061703 | ALLERGAN | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) | |
|
US5061703 (Pediatric) | ALLERGAN | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(8 years ago) | |
Namenda is owned by Allergan.
Namenda contains Memantine Hydrochloride.
Namenda has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Namenda are:
- US5061703
- US5061703*PED
Namenda was authorised for market use on 18 April, 2005.
Namenda is available in solution;oral dosage forms.
Namenda can be used as treatment of moderate to severe dementia of the alzheimer's type.
The generics of Namenda are possible to be released after 11 October, 2015.
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 April, 2005
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: SOLUTION;ORAL
NAMENDA family patents